All Posts Tagged With: "BIIB"
(BIIB) Biogen Analyst Neutral on Shares
We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex,...
21Jan2012 | vitalstocks | 0 comments | Continued(ALNY) Alnylam States Preclinical Data
Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington’s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic...
3Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish
We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological...
8Dec2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment
Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study...
2Dec2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data
Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation...
28Nov2011 | vitalstocks | 0 comments | Continued(BXP) Boston Properties Beats Earnings Estimates
Boston Properties Inc. (BXP), one of the leading real estate investment trusts (REITs), reported third quarter 2011 FFO (funds from operations) of $190.3 million or $1.28 per share, compared with $150.8 million or $1.07 per share in the year-earlier quarter. Fund from operations,...
26Oct2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress
Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates...
6Oct2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic...
30Aug2011 | vitalstocks | 0 comments | Continued(GILD) Take Advantage of the Fire Sale in Healthcare
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts...
18Aug2011 | InvestmentU | 0 comments | Continued(ACOR) Acorda Therapeutics Gains – Earnings Miss Estimates
Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during...
4Aug2011 | vitalstocks | 0 comments | Continued(MS) Merck KGaA Seeks Rebif Extension
Merck KGaA (MKGAF) recently filed a marketing application with the European Medicines Agency (EMA) in its endeavor to expand the label of Rebif, its multiple sclerosis (MS) therapy. The company is seeking approval for Rebif to treat patients who have experienced a single demyelinating...
7Jul2011 | vitalstocks | 0 comments | Continued(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares
We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25. Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer. The company’s lead pipeline candidate, pixantrone, is being developed for...
24Jun2011 | vitalstocks | 0 comments | Continued(MS) Merck KGaA to Withdraw Multiple Sclerosis Drug
Merck KGaA (MKGAF) recently announced its plans to withdraw the regulatory applications filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approval to market cladribine as a treatment for relapsing-remitting multiple sclerosis...
23Jun2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference...
23Jun2011 | vitalstocks | 0 comments | Continued(APOG) Company News for June 23, 2011 – Corporate Summary
• Shares of Robbins & Myers, Inc. (NYSE:RBN) jumped 8.77% on strong fiscal third-quarter profits. The energy equipment supplier said strong customer demand and the recent acquisition of oilfield services has helped the company’s increase its profits • ...
23Jun2011 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec and Partner Elan Announce EU Label Update for Tysabri
Recently, Biogen Idec, Inc. (BIIB) and partner Elan Corporation (ELN) announced that the European Commission (EC) has approved an update to the label for their multiple sclerosis (MS) drug Tysabri (natalizumab) in the European Union (EU). The updated label includes anti-JC Virus...
22Jun2011 | vitalstocks | 0 comments | Continued(CTIC) Cell Therapeutics Posts Positive Pixantrone Data
Cell Therapeutics Inc. (CTIC) recently announced that data from an early stage study of its lead pipeline candidate, pixantrone, for an additional indication, was published in Cancer, an online journal. The study (n=28) tested the efficacy and safety of pixantrone as a combination...
22Jun2011 | vitalstocks | 0 comments | Continued(AFAM) Company News for June 21, 2011 – Corporate Summary
• Manufacturer and distributors of stainless steel and titanium products, Carpenter Technology (NYSE:CRS) has concluded a merger agreement with Latrobe Specialty Metals as per which the former will acquire the latter in a deal worth around $558 million • Shares...
21Jun2011 | vitalstocks | 0 comments | Continued(CTIC) Cell Therapeutics Set to Resubmit Pixantrone NDA
Cell Therapeutics (CTIC) recently met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration (FDA) and received guidance for resubmission of the new drug application (NDA) for its lead pipeline candidate pixantrone. Pixantrone has been developed...
17Jun2011 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra
Acorda Therapeutics, Inc. (ACOR) recently reported an analysis of data on Ampyra (dalfampridine) at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The analysis demonstrated improvements in walking ability of patients on Ampyra as measured by patient self-report...
16Jun2011 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
14Jun2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermesto Buy Elan Unit for $960 Million
Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately...
9May2011 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations
Acorda Therapeutics Inc. (ACOR) posted a loss of 2 cents per share for the first quarter of fiscal 2011, compared with a loss of 56 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 18 cents per share. Despite increased revenues, higher operating...
8May2011 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per...
26Apr2011 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Earnings Report Beats The Street
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per...
23Apr2011 | vitalstocks | 0 comments | Continued(BIIB) Biogen’s Oral Multiple Sclerosis Drug Impresses
Biogen (BIIB) received a boost recently with the company presenting promising top-line data on its oral multiple sclerosis candidate, BG-12. The company presented positive results on the use of BG-12 as a monotherapy in patients suffering from relapsing-remitting multiple sclerosis...
13Apr2011 | vitalstocks | 0 comments | Continued(AA) Company News for April 12, 2011 – Corporate Summary
• Level 3 Communications (NASDAQ:LVLT) and Global Crossing Limited (NASDAQ:GLBC) have entered into a agreement under which Level 3 will acquire Global Crossing in a stock-for-stock transaction • Endo Pharmaceuticals’ (NASDAQ:ENDP) said that it would buy urological...
12Apr2011 | vitalstocks | 0 comments | Continued(PDLI) PDL BioPharma Ramps Up Earnings – Settles Disputes
PDL BioPharma Inc. (PDLI) posted fourth quarter earnings of 20 cents per share, above the year-ago figure of 17 cents. Higher revenues boosted earnings in the quarter. Earnings per share were, however, a penny short of the Zacks Consensus Estimate of 21 cents. For full year 2010,...
7Mar2011 | vitalstocks | 0 comments | Continued(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
2Mar2011 | vitalstocks | 0 comments | Continued